肾移植患者基因多态性对他克莫司药动学和药效学影响的研究进展

摘要/Abstract

摘要： 他克莫司（Tacrolimus，TAC）作为临床上用于器官移植术后抗免疫排斥治疗的一线用药，由于其存在治疗窗窄，血药浓度个体差异大等特点往往给移植患者的器官存活造成很大的影响。药物基因多态性已被证实为导致他克莫司个体间药物代谢动力学特征差异性的主要原因之一，因此本文通过对影响肾移植患者体内他克莫司代谢的相关基因多态性的研究进展进行综述，以为促进TAC在肾移植患者中的临床个体化应用提供参考。

关键词: font-size:medium, ">他克莫司；肾移植；单核苷酸多态性；药动学；药效学

Abstract: Tacrolimus(TAC) is clinically used as a first-line drug for the treatment of anti-immune rejection after organ transplantation. Due to its narrow therapeutic window and large individual differences in blood drug concentration， it often affects the organ survival of transplant patients. great impact. Pharmacogenetic polymorphisms have been confirmed to be one of the main reasons for the differences in the pharmacokinetic characteristics of tacrolimus among individuals. Therefore， this paper analyzes the related single nucleotide polymorphism affecting the metabolism of TAC in kidney transplant patients. The research progress is reviewed to provide some references to promote the individualized clinical administration of tacrolimus in kidney transplant patients.

Key words: font-size:medium, ">Tacrolimus；Kidney Transplantation；Single Nucleotide Polymorphism；Pharmacokinetics；Pharmacodynamics

中图分类号:

杨金伟, 宋沧桑, 李兴德, 张函舒, 王国徽, 宋文彬. 肾移植患者基因多态性对他克莫司药动学和药效学影响的研究进展[J]. 中国药物评价, 2023, 40(1): 23-28.

YANG Jin-wei, SONG Cang-sang, LI Xing-de, ZHANG Han-shu, WANG Guo-hui, SONG Wen-bin. Research Progress on the Effect of Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Tacrolimus in Renal Transplant Patients[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(1): 23-28.

参考文献

[1]Yu M， Liu M， Zhang W， et al. Pharmacokinetics， Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation [J]. Current drug metabolism， 2018， 19(6)： 513-522.
     [2]Radhakrishnan A， Kuppusamy G， Ponnusankar S， et al. Towards next-generation personalization of tacrolimus treatment： a review on advanced diagnostic and therapeutic approaches [J]. Pharmacogenomics， 2021， 22(17)： 1151-1175.
     [3]陈文倩，张雷，张弋，等. 实体器官移植他克莫司个体化治疗专家共识 [J]. 中国医院用药评价与分析， 2021， 21： 1409-1424.
     [4]Birdwell KA， Decker B， Barbarino JM， et al. Clinical Pharmacogenetics Implementation Consortium(CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing [J]. Clinical pharmacology and therapeutics， 2015， 98(1)： 19-24.
     [5]Cheng F， Li Q， Wang J， et al. Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients [J]. Pharmacogenomics and personalized medicine， 2021， 14： 1463-1474.
     [6]Zhai Q， Van Der Lee M， Van Gelder T， et al. Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity [J]. Frontiers in pharmacology， 2022， 13： 1-13.
     [7]Sim SC， Edwards RJ， Boobis AR， et al. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele [J]. Pharmacogenetics and genomics， 2005， 15(9)： 625-631.
     [8]Whirl-Carrillo M， Huddart R， Gong L， et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine [J]. Clinical pharmacology and therapeutics， 2021， 110(3)： 563-572.
     [9]Tamashiro EY， Felipe CR， Genvigir F DV， et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients [J]. Drug Metabolism and Personalized Therapy， 2017， 32(2)： 89-95.
     [10]Li CJ， Li L， Lin L， et al. Impact of the CYP3A5， CYP3A4， COMT， IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients [J]. PLoS One， 2014， 9(1)： 1-9.
     [11]Tamashiro EY， Felipe CR， Genvigir FDV， et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients [J]. Drug Metab Pers Ther， 2017， 32(2)： 89-95.
     [12]Qi G， Han C， Zhou Y， et al. Allele and genotype frequencies of CYP3A4， CYP3A5， CYP3A7， and GSTP1 gene polymorphisms among mainland Tibetan， Mongolian， Uyghur， and Han Chinese populations [J]. Clinical and Experimental Pharmacology and Physiology， 2022， 49(2)： 219-227.
     [13]Liu MZ， He HY， Zhang YL， et al. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients [J]. Acta pharmacologica Sinica， 2017， 38(3)： 415-423.
     [14]Li JL， Liu S， Fu Q， et al. Interactive effects of CYP3A4， CYP3A5， MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients [J]. Pharmacogenomics， 2015， 16(12)： 1355-1365.
     [15]Shi D， Xie T， Deng J， et al. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients [J]. European journal of clinical pharmacology， 2018， 74(6)： 723-729.
     [16]Sohn M， Kim MG， Han N， et al. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients [J]. Scientific reports， 2018， 8(1)： 18064.
     [17]Chen D， Lu H， Sui W， et al. Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients [J]. The pharmacogenomics journal， 2021， 21(3)： 376-389.
     [18]Zhang JJ， Liu SB， Xue L， et al. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients [J]. International journal of clinical pharmacology and therapeutics， 2015， 53(9)： 728-736.
     [19]Zhu W， Xue L， Peng H， et al. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients [J]. Pharmacogenomics， 2018， 19(13)： 1013-1025.
     [20]Ling J， Dong LL， Yang XP， et al. Effects of CYP3A5， ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation [J]. Xenobiotica； the fate of foreign compounds in biological systems， 2020， 50(12)： 1501-1509.
     [21]Lee DH， Lee H， Yoon HY， et al. Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients： A Systematic Review and Meta-Analysis [J]. Pharmaceutics， 2022， 14(2)： 1-9.
     [22]Liu F， Ou YM， Yu AR， et al. Long-Term Influence of CYP3A5， CYP3A4， ABCB1， and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients [J]. Genetic testing and molecular biomarkers， 2017， 21(11)： 663-673.
     [23]Stifft F， Van Kuijk SMJ， Bekers O， et al. Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients [J]. Nephrology， dialysis， transplantation： official publication of the European Dialysis and Transplant Association-European Renal Association， 2018， 33(9)： 1668-1675.
     [24]Turolo S， Edefonti A， Ghio L， et al. CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant [J]. BMC pediatrics， 2020， 20(1)： 1-7.
     [25]马多玲，杨云云，张文文，等. ABCB1多态性对细胞色素P450 3A5*3/*3肾移植受者他克莫司剂量调整血药浓度及肾功能的影响 [J]. 中国临床药理学杂志， 2017， 33： 1874-1877.
     [26]Soda M， Fujitani M， Michiuchi R， et al. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms [J]. Transplant Proc， 2017， 49(6)： 1492-1498.
     [27]李冰玉，梁亚林，史佳佳，等. CYP3A5和ABCB1基因多态性与肾移植术后服用他克莫司患者医院感染的关系 [J]. 中华医院感染学杂志， 2021， 31： 2692-2696.
     [28]Cheng F， Li Q， Wang J， et al. Retrospective Analysis of the Risk Factors of Perioperative Bacterial Infection and Correlation with Clinical Prognosis in Kidney Transplant Recipients [J]. Infection and drug resistance， 2022， 15： 2271-2286.
     [29]Thishya K， Vattam KK， Naushad SM， et al. Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation [J]. PLoS One， 2018， 13(4)： 1-16.
     [30]鲁春云，刘克锋，乔高星，等. MDR1 C1236T和G2677T/A基因多态性对肾移植受者他克莫司血药浓度影响的Meta分析 [J]. 中国医院药学杂志， 2021， 41： 1875-1885.
     [31]Peng W， Lin Y， Zhang H， et al. Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients： A Systematic Review and Meta-analysis [J]. Clinical therapeutics， 2020， 42(10)： 2049-2065.
     [32]Brazeau DA， Attwood K， Meaney CJ， et al. Beyond Single Nucleotide Polymorphisms： CYP3A5*3*6*7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients [J]. Frontiers in genetics， 2020， 11： 889-902.
     [33]Wu Y， Fang F， Wang Z， et al. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation [J]. European journal of clinical pharmacology， 2021， 77(6)： 859-867.
     [34]Boivin AA， Cardinal H， Barama A， et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients [J]. Drug metabolism and pharmacokinetics， 2013， 28(3)： 274-277.
     [35]Lunde I， Bremer S， Midtvedt K， et al. The influence of CYP3A， PPARA， and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients [J]. European journal of clinical pharmacology， 2014， 70(6)： 685-693.
     [36]Everton JBF， Patrício FJB， Faria MS， et al. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients [J]. European journal of clinical pharmacology， 2021， 77(6)： 879-886.
     [37]Elens L， Sombogaard F， Hesselink DA， et al. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus [J]. Pharmacogenetics and genomics， 2013， 23(12)： 649-657.
     [38]Kurzawski M， Malinowski D， Dziewanowski K， et al. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients[J]. Pharmacogenetics and genomics， 2014， 24(8)： 397-400.
     [39]Madsen MJ， Bergmann TK， Brsen K， et al. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients [J]. Drugs in R&D， 2017， 17(2)： 279-286.
     [40]Zhang X， Xu J， Fan J， et al. Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients [J]. Disease markers， 2017， 2017： 7834035-7834043.
     [41]Chen Z， Cheng X， Zhang L， et al. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients [J]. Pharmacological reports： PR， 2021， 73(5)： 1418-1426.
     [42]Liu X， Li J， Fu Q， et al. Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy [J]. Drug metabolism and disposition： the biological fate of chemicals， 2015， 43(4)： 455-458.
     [43]Zhang T， Liu Y， Zeng R， et al. Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation [J]. Liver international： official journal of the International Association for the Study of the Liver， 2018， 38(4)： 724-732.